

SF3A2 Antibody (Center)
Affinity Purified Rabbit Polyclonal Antibody (Pab)
Catalog # AP20040c**Specification**

SF3A2 Antibody (Center) - Product Information

Application	WB,E
Primary Accession	Q15428
Other Accession	Q6AXT8 , Q62203 , A5PJN8 , NP_009096.2
Reactivity	Human
Predicted	Bovine, Mouse, Rat
Host	Rabbit
Clonality	Polyclonal
Isotype	Rabbit IgG
Calculated MW	49256
Antigen Region	166-194

SF3A2 Antibody (Center) - Additional Information**Gene ID** 8175**Other Names**

Splicing factor 3A subunit 2, SF3a66, Spliceosome-associated protein 62, SAP 62, SF3A2, SAP62

Target/Specificity

This SF3A2 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 166-194 amino acids from the Central region of human SF3A2.

Dilution

WB~~1:1000

Format

Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification.

Storage

Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.

Precautions

SF3A2 Antibody (Center) is for research use only and not for use in diagnostic or therapeutic procedures.

SF3A2 Antibody (Center) - Protein Information**Name** SF3A2**Synonyms** SAP62

Function Component of the 17S U2 SnRNP complex of the spliceosome, a large ribonucleoprotein complex that removes introns from transcribed pre-mRNAs (PubMed:[10882114](#), PubMed:[11533230](#), PubMed:[32494006](#), PubMed:[34822310](#)). The 17S U2 SnRNP complex (1) directly participates in early spliceosome assembly and (2) mediates recognition of the intron branch site during pre-mRNA splicing by promoting the selection of the pre-mRNA branch-site adenosine, the nucleophile for the first step of splicing (PubMed:[10882114](#), PubMed:[11533230](#), PubMed:[32494006](#), PubMed:[34822310](#)). Within the 17S U2 SnRNP complex, SF3A2 is part of the SF3A subcomplex that contributes to the assembly of the 17S U2 snRNP, and the subsequent assembly of the pre-spliceosome 'E' complex and the pre-catalytic spliceosome 'A' complex (PubMed:[10882114](#), PubMed:[11533230](#)). Involved in pre-mRNA splicing as a component of pre-catalytic spliceosome 'B' complexes, including the Bact complex (PubMed:[29360106](#), PubMed:[29361316](#), PubMed:[30315277](#)). Interacts directly with the duplex formed by U2 snRNA and the intron (PubMed:[29360106](#)).

Cellular Location


Nucleus {ECO:0000255|PROSITE-ProRule:PRU00130, ECO:0000269|PubMed:10882114, ECO:0000269|PubMed:21349847, ECO:0000269|PubMed:29360106, ECO:0000269|PubMed:29361316, ECO:0000269|PubMed:30315277}

SF3A2 Antibody (Center) - Protocols

Provided below are standard protocols that you may find useful for product applications.

- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)

SF3A2 Antibody (Center) - Images



SF3A2 Antibody (Center) (Cat. #AP20040c) western blot analysis in Jurkat cell line lysates (35ug/lane). This demonstrates the SF3A2 antibody detected the SF3A2 protein (arrow).

SF3A2 Antibody (Center) - Background

This gene encodes subunit 2 of the splicing factor 3a

protein complex. The splicing factor 3a heterotrimer includes subunits 1, 2 and 3 and is necessary for the in vitro conversion of 15S U2 snRNP into an active 17S particle that performs pre-mRNA splicing. Subunit 2 interacts with subunit 1 through its amino-terminus while the single zinc finger domain of subunit 2 plays a role in its binding to the 15S U2 snRNP. Subunit 2 may also function independently of its RNA splicing function as a microtubule-binding protein.

SF3A2 Antibody (Center) - References

Rose, J. Phd, et al. Mol. Med. (2010) In press :
Tanackovic, G., et al. Mol. Biol. Cell 16(3):1366-1377(2005)
Nesic, D., et al. J. Cell. Sci. 117 (PT 19), 4423-4433 (2004) :
Takenaka, K., et al. Biochem. J. 382 (PT 1), 223-230 (2004) :
Colland, F., et al. Genome Res. 14(7):1324-1332(2004)